Cambrex Marks Significant Expansion in U.S. and Europe with New Facilities

Cambrex's Strategic Expansion: Moving Forward in Pharmaceutical Manufacturing

Cambrex, a premier global contract development and manufacturing organization (CDMO), has revealed its commitment to expanding operations in both the United States and Europe. As part of a substantial investment plan, Cambrex has completed crucial engineering studies for a brand-new, large-scale active pharmaceutical ingredient (API) manufacturing facility in Charles City, Iowa. This endeavor represents a pivotal step towards enhancing their manufacturing capabilities with a remarkable $120 million investment.

New Manufacturing Facility in Iowa

The upcoming plant in Charles City is set to introduce a capacity of 140,000 liters, integrating advanced technology such as large-scale and mid-scale reactors and sophisticated Hastelloy agitated filter dryers. These enhancements to Cambrex’s existing manufacturing suites will culminate in a 20% increase in large-scale manufacturing capabilities upon completion. Designed to accommodate complex chemistry, including controlled substances and highly potent APIs (HPAPI), this expansion positions Cambrex as a vital partner for pharmaceutical innovators looking to advance their products.

Groundbreaking for this new facility is scheduled for late 2026, marking a significant milestone in Cambrex's growth trajectory. With this initiative, Cambrex aims to not only enhance its service offerings but also solidify its status as a leader in the pharmaceutical manufacturing sector.

Expanding Horizons in Europe

While Cambrex is making significant strides in the U.S., the company's commitment to growth is equally evident across the Atlantic. A $30 million expansion project is currently underway at their Milan, Italy site. This project is set to elevate the site’s analytical development and process R&D capabilities. Upgrades to several production plants are also included, ensuring that Cambrex can meet the increasing demand for complex drug formulations and manufacturing capabilities.

Expected to wrap up in the latter half of 2027, the Milan expansion reflects Cambrex's dedication to adapting to market needs. Notably, this year, the Milan site also celebrates its 80th anniversary, marking a legacy of supporting pharmaceutical development and manufacturing excellence.

Claudio Russolo, Cambrex’s Chief Operating Officer, stated, "Our Milan, Italy site has a distinguished legacy of supporting pharmaceutical development and manufacturing. We are committed to ongoing investments to meet the growing market demand for complex chemistries, including tides, highly potent molecules, and controlled substances."

Commitment to Innovation and Excellence

Cambrex’s relentless focus on innovation and operational excellence is not just about expanding their physical footprint; it reflects a broader commitment to modernizing solutions for drug development. The company's approach prioritizes a science-first methodology aimed at supporting the next generation of life-changing therapies. As the pharmaceutical landscape continues to evolve, Cambrex is well-positioned to provide cutting-edge resource solutions to its clients.

About Cambrex

With a rich history of over 45 years and a dedicated team of 2,000 professionals, Cambrex stands at the forefront of the pharmaceutical contract development and manufacturing industry. The company specializes in a comprehensive range of skills, including continuous flow processing, controlled substance management, peptide synthesis, solid-state science, material characterization, and the development of highly potent APIs. Cambrex’s commitment to improving drug substance technologies ensures it remains an essential partner for pharmaceutical companies worldwide.

As Cambrex advances its operations with strategic expansions in both the United States and Europe, the pharmaceutical industry awaits to see how these developments will impact drug manufacturing and R&D capabilities in the coming years.